A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium

被引：1

作者：

Lenti, M., V ^{[1
,2
]}

Ribaldone, D. G. ^{[3
]}

de Andreis, F. Borrelli ^{[1
,27
]}

Vernero, M. ^{[3
]}

Barberio, B. ^{[4
]}

De Ruvo, M. ^{[4
]}

Savarino, E., V ^{[4
]}

Kav, T. ^{[5
]}

Blesl, A. ^{[6
]}

Franzoi, M. ^{[7
]}

Groechenig, H. P. ^{[7
]}

Pugliese, D. ^{[8
,9
,30
]}

Ianiro, G. ^{[8
,9
]}

Porcari, S. ^{[8
,9
]}

Cammarota, G. ^{[8
,9
]}

Gasbarrini, A. ^{[8
,9
]}

Spagnuolo, R. ^{[10
]}

Ellul, P. ^{[11
]}

Foteinogiannopoulou, K. ^{[12
]}

Koutroubakis, I. ^{[12
]}

Argyriou, K. ^{[13
]}

Cappello, M. ^{[14
]}

Jauregui-Amezaga, A. ^{[15
,29
]}

Demarzo, M. G. ^{[16
]}

Silvestris, N. ^{[17
]}

Armuzzi, A. ^{[18
,28
]}

Sottotetti, F. ^{[19
]}

Bertani, L. ^{[20
]}

Festa, S. ^{[21
]}

Eder, P. ^{[22
]}

Pedrazzoli, P. ^{[1
,23
]}

Lasagna, A. ^{[23
]}

Vanoli, A. ^{[24
,25
]}

Gambini, G. ^{[26
]}

Santacroce, G. ^{[1
,2
]}

Rossi, C. M. ^{[1
,2
]}

Delliponti, M. ^{[2
]}

Klersy, C. ^{[26
]}

Corazza, G. R. ^{[1
,2
]}

Di Sabatino, A. ^{[1
,2
]}

Mengoli, C. ^{[2
]}

Aronico, N. ^{[2
]}

Lepore, F. ^{[1
,2
]}

Broglio, G. ^{[1
]}

Merli, S. ^{[2
]}

Natalello, G. ^{[2
]}

Alimenti, E. ^{[1
]}

Scalvini, D. ^{[1
]}

Muscarella, S. ^{[14
]}

Agustoni, F. ^{[1
,23
]}

机构：

[1] Univ Pavia, Dept Internal Med & Med Therapeut, Pavia, Italy

[2] Fdn IRCCS Policlin San Matteo, Dept Internal Med 1, Pavia, Italy

[3] Univ Turin, Dept Med Sci, Div Gastroenterol, Turin, Italy

[4] Univ Padua, Dept Surg Oncol & Gastroenterol, Div Gastroenterol, Padua, Italy

[5] Hacettepe Univ, Sch Med, Dept Gastroenterol, Ankara, Turkiye

[6] Med Univ Graz, Dept Internal Med, Div Gastroenterol & Hepatol, Graz, Austria

[7] Acad Teaching Hosp Bros St John God, Dept Internal Med & Gastroenterol, St Veit An Der Glan, Austria

[8] Policlin Univ A Gemelli IRCCS Fdn, CEMAD Digest Dis Ctr, Dept Med & Surg Sci, Rome, Italy

[9] Univ Cattolica Sacro Cuore Roma, Dept Translat Med & Surg, Rome, Italy

[10] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy

[11] Mater Dei Hosp, Dept Med, Div Gastroenterol, Msida, Malta

[12] Univ Hosp Heraklion, Dept Gastroenterol, Iraklion, Crete, Greece

[13] Univ Hosp Larisa, Dept Gastroenterol, Larisa, Greece

[14] Univ Palermo, Gastroenterol & Hepatol Sect, PROMISE, Palermo, Italy

[15] Univ Hosp Antwerp, Dept Gastroenterol & Hepatol, Antwerp, Belgium

[16] Univ Genoa, Osped Policlin San Martino IRCCS Oncol, Dept Internal Med, Gastroenterol Unit, Genoa, Italy

[17] Univ Messina, Dept Human Pathol Adulthood & Childhood DETEV G B, Med Oncol Unit, Messina, Italy

[18] IRCCS Humanitas Res Hosp, IBD Ctr, Milan, Italy

[19] Ist Clinici Sci Maugeri IRCCS, Med Oncol Unit, Pavia, Italy

[20] Pontedera Hosp, Dept Gen Surg & Gastroenterol, Tuscany North West ASL, Pontedera, Italy

[21] Osped S Filippo Neri, IBD Unit, Rome, Italy

[22] Poznan Univ Med Sci, Dept Gastroenterol Dietet & Internal Dis, Poznan, Poland

[23] Fdn IRCCS Policlin San Matteo, Med Oncol Unit, Pavia, Italy

[24] Univ Pavia, Dept Mol Med, Unit Anat Pathol, Pavia, Italy

[25] IRCCS San Matteo Hosp Fdn, Pavia, Italy

[26] Fdn IRCCS Policlin San Matteo, Clin Epidemiol & Biometry Serv, Pavia, Italy

[27] Isola Tiberina Gemelli Isola Hosp, Digest Endoscopy Unit, Rome, Italy

[28] Humanitas Univ, Dept Biomed Sci, Milan, Italy

[29] Univ Antwerp, Fac Med & Hlth Sci, Div Gastroenterol Hepatol, LEMP, Antwerp, Belgium

[30] Osped Isola Tiberina Gemelli Isola, UOS Gastroenterol, Rome, Italy

[31] Univ Trieste, Dept Med Surg & Hlth Sci, Trieste, Italy

[32] Ctr Riferimento Oncol Aviano CRO, Oncol Gastroenterol, Aviano, Italy

[33] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Gastroenterol & Endoscopy Unit, Milan, Italy

[34] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy

[35] Santa Maria del Prato Hosp, Dept Gastrointestinal Oncol Surg, Gastroenterol Unit, Feltre, Italy

[36] Natl Inst Res Saverio Bellis, Dept Gastroenterol, Bari, Italy

[37] Natl Inst Res Saverio Bellis, Digest Endoscopy Unit, Bari, Italy

[38] Ist Clin Sci Maugeri IRCCS, Pavia Inst, Gastroenterol Unit, Pavia, Italy

[39] AOU Renato Dulbecco, Catanzaro, Italy

[40] Univ Gen Hosp Larissa, Dept Med Oncol, Larisa, Greece

来源：

ESMO OPEN | 2024年 / 9卷 / 07期

关键词：

colitis; immunotherapy; in fl iximab; nivolumab; pembrolizumab;

D O I：

10.1016/j.esmoop.2024.103632

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Data regarding the clinical outcome of patients with immune checkpoint inhibitor (ICI)-induced colitis are scant. We aimed to describe the 12-month clinical outcome of patients with ICI-induced colitis. Materials and methods: This was a retrospective, European, multicentre study. Endoscopy/histology-proven ICIinduced colitis patients were enrolled. The 12-month clinical remission rate, de fi ned as a Common Terminology Criteria for Adverse Events diarrhoea grade of 0-1, and the correlates of 12-month remission were assessed. Results: Ninety-six patients [male:female ratio 1.5:1; median age 65 years, interquartile range (IQR) 55.5-71.5 years] were included. Lung cancer (41, 42.7%) and melanoma (30, 31.2%) were the most common cancers. ICI-related gastrointestinal symptoms occurred at a median time of 4 months (IQR 2-7 months). An in fl ammatory bowel disease (IBD)-like pattern was present in 74 patients (77.1%) [35 (47.3%) ulcerative colitis (UC)-like, 11 (14.9%) Crohn ' s disease (CD)-like, 28 (37.8%) IBD-like unclassi fi ed], while microscopic colitis was present in 19 patients (19.8%). As a fi rst line, systemic steroids were the most prescribed drugs (65, 67.7%). The 12-month clinical remission rate was 47.7 per 100 person-years [95% con fi dence interval (CI) 33.5-67.8). ICI was discontinued due to colitis in 66 patients (79.5%). A CD-like pattern was associated with remission failure (hazard ratio 3.84, 95% CI 1.16-12.69). Having histopathological signs of microscopic colitis ( P = 0.049) and microscopic versus UC-/CD-like colitis ( P = 0.014) were associated with a better outcome. Discontinuing the ICI was not related to the 12-month remission ( P = 0.483). Four patients (3.1%) died from ICI-induced colitis. Conclusions: Patients with IBD-like colitis may need an early and more aggressive treatment. Future studies should focus on how to improve long-term clinical outcomes.

引用

页数：10

共 32 条

[1] Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis
Abu-Sbeih, Hamzah
Ali, Faisal S.
Wang, Xuemei
Mallepally, Niharika
Chen, Ellie
Altan, Mehmet
Bresalier, Robert S.
Charabaty, Aline
Dadu, Ramona
Jazaeri, Amir
Lashner, Bret
Wang, Yinghong
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[2] Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab
Alexander, James L.
Ibraheim, Hajir
Sheth, Bhavisha
Little, Jessica
Khan, Muhammad Saheb
Richards, Camellia
Hunter, Nikki
Chauhan, Dharmisha
Ratnakumaran, Raguprakash
McHugh, Kathleen
Pinato, David J.
Nathan, Paul
Choy, Julia
Crusz, Shanthini M.
Furness, Andrew
Turajlic, Samra
Pickering, Lisa
Larkin, James
Teare, Julian P.
Papa, Sophie
Speight, Ally
Sharma, Anand
Powell, Nick
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (07)
[3] [Anonymous], CANC THERAPY EVALUAT
[4] Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
Bagchi, Sreya
Yuan, Robert
Engleman, Edgar G.
[J]. ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021, 2021, 16 : 223 - 249
[5] A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION
CHARLSON, ME
POMPEI, P
ALES, KL
MACKENZIE, CR
[J]. JOURNAL OF CHRONIC DISEASES, 1987, 40 (05): : 373 - 383
[6] Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies
Chen, Jonathan H.
Pezhouh, Maryam K.
Lauwers, Gregory Y.
Masia, Ricard
[J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2017, 41 (05) : 643 - 654
[7] Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
Cheung, Vincent Ting Fung
Gupta, Tarun
Olsson-Brown, Anna
Subramanian, Sreedhar
Sasson, Sarah Christina
Heseltine, Jonathan
Fryer, Eve
Collantes, Elena
Sacco, Joseph J.
Pirmohamed, Munir
Simmons, Alison
Klenerman, Paul
Tuthill, Mark
Protheroe, Andrew S.
Chitnis, Meenali
Fairfax, Benjamin Peter
Payne, Miranda Jane
Middleton, Mark Ross
Brain, Oliver
[J]. BRITISH JOURNAL OF CANCER, 2020, 123 (02) : 207 - 215
[8] Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report
d'Apolito, Maria
Spagnuolo, Rocco
Siciliano, Maria Anna
Barbieri, Vito
Cosco, Cristina
Fiorillo, Lucia
Cuomo, Onofrio
Zuccala, Valeria
Correale, Pierpaolo
Pensabene, Licia
Rossi, Marco
Doldo, Patrizia
Tassone, Pierfrancesco
Tagliaferri, Pierosandro
[J]. THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2022, 13
[9] AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review
Dougan, Michael
Wang, Yinghong
Rubio-Tapia, Alberto
Lim, Joseph K.
[J]. GASTROENTEROLOGY, 2021, 160 (04) : 1384 - 1393
[10] Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management
Foppen, Marnix H. Geukes
Rozeman, Elisa A.
van Wilpe, Sandra
Postma, Cindy
Snaebjornsson, Petur
van Thienen, Johannes V.
van Leerdam, Monique E.
van den Heuvel, Michel
Blank, Christian U.
van Dieren, Jolanda
Haanen, John B. A. G.
[J]. ESMO OPEN, 2018, 3 (01)

← 1 2 3 4 →